Return to search

Overexpression of active AKT3 induces differential binding of coregulator proteins to the estrogen receptor as a possible mechanism of Tamoxifen resistance

Tamoxifen is an effective anti-estrogen for treatment of women with hormonedependent breast cancer but acquired drug resistance limits its therapeutic benefit. We have previously reported that expression of active Akt3 in MCF-7 breast cancer cells results in estrogen-independent tumors that are actually stimulated to grow after tamoxifen treatment. We hypothesize that this tamoxifen resistance may be attributed to binding of different co-regulator proteins and/or different binding affinity of these proteins to the estrogen receptor in M CF-7 cells overexpressing active Akt3 as compared to parental MCF-7 cells. We have immuno-precipitated the estrogen receptor along with bound co-regulator proteins in both cells lines after tamoxifen, estradiol, or vehicle treatment. After 2-D gel electrophoresis separation of these immuno-precipitated proteins and comparing them using PDQuest 2-D analysis software, we identified protein spots that were statistically different under the treatment conditions between the two cell lines. The isolated protein spots were subjected to MALDI-TOF mass spectrometry. By searching protein databases through the MASCOT website for protein identification, we have identified estrogen receptor co-regulator proteins that may play a potential role in tamoxifen resistance. Current studies are focused on addressing the role of differential protein binding as a possible mechanism of tamoxifen resistance in Akt3 over-expressing breast cancer cells.

Identiferoai:union.ndltd.org:pacific.edu/oai:scholarlycommons.pacific.edu:uop_etds-1687
Date01 January 2008
CreatorsHagras, Muhammad A.
PublisherScholarly Commons
Source SetsUniversity of the Pacific
Detected LanguageEnglish
Typetext
Formatapplication/pdf
SourceUniversity of the Pacific Theses and Dissertations

Page generated in 0.0051 seconds